医学阅读软件-医学补充阅读：FDANews

the food and drug administration today approved emsam (selegiline), the first skin (transdermal) patch for use in treating major depression. the once a day patch works by delivering selegiline, a monoamine oxidase inhibitor or maoi, through the skin and into the bloodstream. at its lowest strength, emsam can be used without the dietary restrictions that are needed for all oral mao inhibitors that are approved for treating major depression.

　　"emsam provides a significant advance because at least in its lowest dose patients can use the drug without the usual dietary restrictions associated with these types of drugs known as mao inhibitors,“ said dr. steven galson, director for the center for drug evaluation and research.

　　major depressive disorder is a common psychiatric condition in the u.s. population. symptoms of depression include general emotional dejection, withdrawal and restlessness that interfere with daily functioning, such as loss of interest in usual activities; significant change in weight and/or appetite; insomnia; increased fatigue; feelings of guilt or worthlessness; slowed thinking or impaired concentration; and a suicide attempt or suicidal ideation.

　　mao inhibitors usually require specific dietary restrictions because when combined with certain foods they can cause a sudden, large increase in blood pressure, or “hypertensive crisis”. a hypertensive crisis can lead to a stroke and death. symptoms of a hypertensive crisis include sudden onset of severe headache, nausea, stiff neck, a fast heartbeat or a change in the way your heart beats (palpitations), sweating, and confusion. patients who have these symptoms should get medical care right away.

本文来源：https://www.wddqw.com/VZKP.html